The earnings call presented a strategic refocus on key assets with promising clinical progress and financial stability. However, there are challenges such as the departure of the CSO and uncertainty around the ANKET program. Despite these lowlights, the highlights significantly outweigh them, suggesting a positive outlook.

Company Guidance

During the Innate Pharma First Half 2025 Business Update and Financial Results Conference Call, the company provided comprehensive guidance on its strategic focus and financial projections. The key takeaway from the call was Innate's decision to concentrate its investment on three high-value clinical assets: IPH4502, lacutamab, and monalizumab. The company plans to complete enrollment for IPH4502's Phase I study by Q1 2026 and anticipates reporting preliminary data in the first half of 2026. Lacutamab is preparing for a Phase III trial with potential accelerated approval by 2027, while monalizumab's Phase III PACIFIC-9 trial, in collaboration with AstraZeneca, is expected to yield data in the second half of 2026. Financially, Innate reported EUR 70.4 million in cash, sufficient to fund operations until the end of Q3 2026, which includes the impact of a planned organizational restructuring. This strategic focus aims to align the company's science, organization, and investments to drive forward programs with the greatest potential impact for patients and shareholders.

Strong Clinical Pipeline Focus

Innate Pharma has strategically decided to focus on three high-value clinical assets: IPH4502, lacutamab, and monalizumab. This decision is aimed at maximizing impact for patients and shareholders.

Progress in IPH4502 Development

IPH4502 is currently in Phase I development with promising preclinical data indicating potential efficacy beyond urothelial cancer. Enrollment is progressing well, with completion expected by Q1 2026. Preliminary safety and activity data are anticipated in the first half of 2026.

Lacutamab FDA Breakthrough Therapy Designation

Lacutamab received FDA breakthrough therapy designation for relapsed or refractory Sézary syndrome, highlighting its potential to accelerate development and regulatory review.

Monalizumab Phase III Progress

The Phase III PACIFIC-9 trial by AstraZeneca is fully recruited, with primary completion expected in the first half of 2026 and data anticipated in the second half of 2026.

Financial Stability

Innate Pharma reported EUR 70.4 million in cash, providing a runway until the end of Q3 2026. Operating expenses decreased by 29% compared to the prior year.

Innate Pharma (IPHA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IPHA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 19, 2026	2025 (Q4)	-0.37 / -	-0.346	―	―	―
Sep 17, 2025	2025 (Q2)	-0.33 / -0.30	-0.342	13.45% (+0.05)
Mar 27, 2025	2024 (Q4)	-0.27 / -0.35	-0.13	-166.15% (-0.22)
Sep 12, 2024	2024 (Q2)	-0.30 / -0.34	0.021	-1728.57% (-0.36)
Mar 21, 2024	2023 (Q4)	-0.44 / -0.13	-0.88	85.23% (+0.75)
Sep 14, 2023	2023 (Q2)	0.09 / 0.02	0.08	-73.75% (-0.06)
Mar 23, 2023	2022 (Q4)	-0.41 / -0.88	-0.378	-132.80% (-0.50)
Sep 15, 2022	2022 (Q2)	0.38 / 0.08	-0.355	122.54% (+0.43)	―	―
Mar 24, 2022	2021 (Q4)	-0.19 / -0.38	-0.811	53.39% (+0.43)	―	―
Sep 15, 2021	2021 (Q2)	-0.30 / -0.35	-0.083	-327.71% (-0.27)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IPHA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 17, 2025	$2.08	$2.05	-1.44%
Mar 27, 2025	$1.81	$1.97	+8.84%
Sep 12, 2024	$2.36	$2.28	-3.39%
Mar 21, 2024	$2.50	$2.41	-3.60%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Innate Pharma (IPHA) report earnings?

Innate Pharma (IPHA) is schdueled to report earning on Mar 19, 2026, Before Open (Confirmed).

What is Innate Pharma (IPHA) earnings time?

Innate Pharma (IPHA) earnings time is at Mar 19, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IPHA EPS forecast?

IPHA EPS forecast for the fiscal quarter 2025 (Q4) is -0.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing